|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.23/-0.25
|
企業價值
13.87B
|
資產負債 |
每股賬面淨值
0.59
|
現金流量 |
現金流量率
--
|
損益表 |
收益
17.50M
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/24 12:48 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate isridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |